Biotech Values

[DewDiligence]

Follow-up questions re generic Neurontin:

1. Your list of companies that have launched matches the list of approved ANDA’s in the drugs@fda database with the following exceptions: American Health, GSMS, Unit Dose Labs, and United Research Labs are on your list but not the drugs@fda list; Interpharm and Watson are on the drugs@fda list but not on your list. Are some of the names on your list licensees of Interpharm or Watson? If not, is the drugs@fda list simply unreliable?

2. Do treble damages apply in this case if PFE prevails at trial?

3. Do you expect that any of the generic entrants will voluntarily cease marketing as a result of the appellate decision to order a trial?

T.i.a. Dew